Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Evotec AG (EVO), Shoulder Innovations, Inc. (SI) and Bausch + Lomb Corporation (BLCO)

Tipranks - Thu Mar 12, 5:54AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evotec AG (EVOResearch Report), Shoulder Innovations, Inc. (SIResearch Report) and Bausch + Lomb Corporation (BLCOResearch Report).

Claim 70% Off TipRanks Premium

Evotec AG (EVO)

In a report released today, Michael Ryskin from Bank of America Securities maintained a Sell rating on Evotec AG, with a price target of $3.00. The company’s shares closed last Tuesday at $2.67.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 1.7% and a 49.2% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Evotec AG has an analyst consensus of Hold, with a price target consensus of $3.50.

See the top stocks recommended by analysts >>

Shoulder Innovations, Inc. (SI)

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Shoulder Innovations, Inc., with a price target of $24.00. The company’s shares closed last Tuesday at $13.05.

According to TipRanks.com, Zimmerman is a 2-star analyst with an average return of 0.0% and a 40.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Tactile Systems Technology, and Organogenesis Holdings. ;'>

Shoulder Innovations, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $22.00.

Bausch + Lomb Corporation (BLCO)

Citi analyst Joanne Wuensch reiterated a Buy rating on Bausch + Lomb Corporation today and set a price target of $21.00. The company’s shares closed last Tuesday at $17.12.

According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 3.8% and a 55.8% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Bausch + Lomb Corporation with a $18.82 average price target, which is a 10.1% upside from current levels. In a report issued on March 3, Morgan Stanley also maintained a Buy rating on the stock with a $21.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.